138
Participants
Start Date
August 12, 2022
Primary Completion Date
July 1, 2025
Study Completion Date
July 1, 2027
UV1
UV1 vaccine
Sagramostim
for stimulation of local dendritic cell population to take up the vaccine and to mature into professional APCs
Anti-PD-1/PD-L1 treatment
either pembrolizumab, atezolizumab or cemiplimab
RECRUITING
Vestre Viken Health Trust, Drammen
University Hospital, Akershus
OTHER
Oslo University Hospital
OTHER
Haukeland University Hospital
OTHER
Helse Stavanger HF
OTHER_GOV
Helse Fonna
OTHER
Helse Nord-Trøndelag HF
OTHER
St. Olavs Hospital
OTHER
Alesund Hospital
OTHER
Helse Forde
OTHER
University Hospital of North Norway
OTHER
Vestre Viken Hospital Trust
OTHER